Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Valeant Pharmaceuticals
Valeant Pharmaceuticals
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Adare expands global handling & packaging capabilities
The company will have enhanced compaction, milling, bin blending and tablet compression capabilities in Philadelphia, Ohio and Milan
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
Sobi enters into new distribution agreement with Valeant for Ammonul
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here
to find out more.
Media
A precision medicine approach to developing cancer vaccines
Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build
Valeant Canada expands with $27.5m investment
The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec
Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive
He brings more than 30 years of leadership and operations experience in healthcare to the firm
Valeant Pharmaceuticals makes management change
In its US Dermatology and Gastrointestinal businesses
J. Michael Pearson returns as CEO of Valeant following illness
Robert A. Ingram appointed Chairman of the Board as the roles of Chairman and CEO are separated
Regulatory
Opinion: Politics, passion and patient power
Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Subscribe now